See more : Microchip Technology Inc (MCP.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Humana Inc. (HUM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humana Inc., a leading company in the Medical – Healthcare Plans industry within the Healthcare sector.
You may be interested
- Orinoquia Real Estate SOCIMI, S.A. (MLORQ.PA) Income Statement Analysis – Financial Results
- Hon Hai Precision Industry Co., Ltd. (2317.TW) Income Statement Analysis – Financial Results
- Lottery.com Inc. (LTRYW) Income Statement Analysis – Financial Results
- Barsele Minerals Corp. (BRSLF) Income Statement Analysis – Financial Results
- Riso Kagaku Corporation (6413.T) Income Statement Analysis – Financial Results
Humana Inc. (HUM)
About Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.37B | 92.87B | 83.06B | 77.16B | 64.89B | 56.91B | 53.77B | 54.38B | 54.29B | 48.50B | 41.31B | 39.13B | 36.83B | 33.87B | 30.96B | 28.95B | 25.29B | 21.42B | 14.42B | 13.10B | 12.23B | 11.26B | 10.19B | 10.51B | 10.11B | 9.78B | 8.04B | 6.79B | 4.70B | 3.65B | 3.14B | 4.04B | 5.87B | 4.85B |
| Cost of Revenue | 13.19B | 12.67B | 10.12B | 10.05B | 7.38B | 7.53B | 6.57B | 7.28B | 7.32B | 7.64B | 6.36B | 5.83B | 5.40B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 93.19B | 80.20B | 72.94B | 67.10B | 57.51B | 49.39B | 47.20B | 47.10B | 46.97B | 40.86B | 34.96B | 33.30B | 31.44B | 33.87B | 30.96B | 28.95B | 25.29B | 21.42B | 14.42B | 13.10B | 12.23B | 11.26B | 10.19B | 10.51B | 10.11B | 9.78B | 8.04B | 6.79B | 4.70B | 3.65B | 3.14B | 4.04B | 5.87B | 4.85B |
| Gross Profit Ratio | 87.60% | 86.36% | 87.82% | 86.97% | 88.63% | 86.78% | 87.79% | 86.62% | 86.52% | 84.25% | 84.62% | 85.10% | 85.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.40B | 4.66B | 4.23B | 3.94B | 3.48B | 3.02B | 2.18B | 1.88B | 1.86B | 1.74B | 1.55B | 1.44B | 1.37B | 1.33B | 1.12B | 940.00M | 571.00M | 436.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 12.20B | 10.12B | 10.05B | 7.38B | 7.53B | 6.42B | 7.17B | 7.30B | 7.64B | 6.36B | 5.83B | 5.40B | 4.66B | 4.23B | 3.94B | 3.48B | 3.02B | 2.18B | 1.88B | 1.86B | 1.74B | 1.55B | 1.44B | 1.37B | 1.33B | 1.12B | 940.00M | 571.00M | 436.00M | 368.00M | 371.00M | 226.00M | 226.40M |
| Other Expenses | 102.36B | 76.87B | 69.20B | 62.15B | 53.80B | 47.10B | 43.09B | 45.47B | 44.38B | 38.50B | 32.90B | 31.28B | 29.09B | 27.08B | 24.81B | 23.93B | 20.46B | 17.57B | 11.80B | 10.79B | 10.01B | -12.77B | 8.44B | 8.93B | -11.85B | -10.86B | -8.86B | -7.70B | -4.97B | -3.81B | -3.36B | -4.11B | -5.44B | -4.48B |
| Operating Expenses | 102.36B | 89.07B | 79.32B | 72.20B | 61.18B | 54.62B | 49.51B | 52.64B | 51.67B | 46.14B | 39.25B | 37.11B | 34.49B | 31.74B | 29.04B | 27.87B | 23.93B | 20.59B | 13.98B | 12.67B | 11.86B | -11.03B | 9.99B | 10.37B | -10.48B | -9.53B | -7.75B | -6.76B | -4.40B | -3.37B | -2.99B | -3.74B | -5.21B | -4.25B |
| Cost & Expenses | 102.36B | 89.07B | 79.32B | 72.20B | 61.18B | 54.62B | 49.51B | 52.64B | 51.67B | 46.14B | 39.25B | 37.11B | 34.60B | 32.12B | 29.36B | 27.95B | 24.00B | 20.65B | 14.00B | 12.69B | 11.88B | 11.05B | 10.01B | 10.40B | 10.52B | 9.58B | 7.77B | 6.77B | 4.41B | 3.40B | 422.00M | 680.00M | 579.00M | 568.60M |
| Interest Income | 0.00 | 401.00M | 326.00M | 283.00M | 242.00M | 218.00M | 242.00M | 189.00M | 186.00M | 192.00M | 140.00M | 105.00M | 0.00 | 60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 493.00M | 401.00M | 326.00M | 283.00M | 242.00M | 218.00M | 242.00M | 189.00M | 186.00M | 192.00M | 140.00M | 105.00M | 109.00M | 105.06M | 105.84M | 80.29M | 68.88M | 63.14M | 39.32M | 23.17M | 17.37M | 17.25M | 25.30M | 29.00M | 33.00M | 47.00M | 20.00M | 11.00M | 11.00M | 25.00M | 7.00M | 71.00M | 97.00M | 111.30M |
| Depreciation & Amortization | 917.00M | 845.00M | 713.00M | 616.00M | 575.00M | 534.00M | 485.00M | 465.00M | 447.00M | 449.00M | 426.00M | 338.00M | 303.00M | 262.91M | 250.27M | 220.35M | 184.81M | 148.60M | 128.86M | 117.79M | 126.78M | 120.73M | 171.02M | 147.00M | 124.00M | 128.00M | 108.00M | 98.00M | 70.00M | 50.00M | 47.00M | 238.00M | 256.00M | 230.90M |
| EBITDA | 4.93B | 4.68B | 4.34B | 5.45B | 4.17B | 2.85B | 4.75B | 2.21B | 3.06B | 2.81B | 2.49B | 2.35B | 2.54B | 2.12B | 1.85B | 1.29B | 1.47B | 910.68M | 550.57M | 533.64M | 488.86M | 347.92M | 369.91M | 290.00M | -247.45M | 331.00M | 128.00M | 116.00M | 81.00M | 307.00M | 54.00M | 309.00M | 353.00M | 342.20M |
| EBITDA Ratio | 4.63% | 5.00% | 5.37% | 7.22% | 6.61% | 4.97% | 8.83% | 4.06% | 5.64% | 5.80% | 6.02% | 6.02% | 6.89% | 5.94% | 5.98% | 4.19% | 5.83% | 4.25% | 3.82% | 4.07% | 3.86% | 2.94% | 3.47% | 2.48% | -2.77% | 3.38% | 4.70% | 1.71% | 7.61% | 8.40% | 88.05% | 89.07% | 94.49% | 93.04% |
| Operating Income | 4.01B | 3.80B | 3.75B | 4.96B | 3.71B | 2.29B | 4.26B | 1.74B | 2.62B | 2.36B | 2.06B | 2.02B | 2.24B | 1.75B | 1.60B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 344.72M | 209.93M | 183.08M | 114.00M | -404.00M | 203.00M | 270.00M | 18.00M | 288.00M | 257.00M | 2.72B | 3.36B | 5.29B | 4.28B |
| Operating Income Ratio | 3.77% | 4.09% | 4.51% | 6.42% | 5.72% | 4.03% | 7.93% | 3.20% | 4.82% | 4.87% | 4.99% | 5.15% | 6.07% | 5.17% | 5.17% | 3.43% | 5.10% | 3.56% | 2.92% | 3.17% | 2.82% | 1.86% | 1.80% | 1.08% | -3.99% | 2.08% | 3.36% | 0.27% | 6.13% | 7.03% | 86.55% | 83.18% | 90.13% | 88.28% |
| Total Other Income/Expenses | -630.00M | -232.00M | -391.00M | -386.00M | 264.00M | -1.04B | -242.00M | -189.00M | 84.00M | -192.00M | -140.00M | -105.00M | 5.29B | -105.06M | -105.84M | -80.29M | -68.69M | -63.45M | -20.41M | -23.17M | 0.00 | 0.00 | 0.00 | 0.00 | -404.84M | 203.08M | 0.00 | 0.00 | 0.00 | 257.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 3.38B | 3.57B | 3.35B | 4.60B | 3.46B | 2.06B | 4.02B | 1.55B | 2.43B | 2.17B | 1.92B | 1.91B | 2.24B | 1.75B | 1.60B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 344.72M | 209.93M | 183.08M | 114.00M | -404.00M | 203.00M | 270.00M | 18.00M | 288.00M | 257.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 3.18% | 3.84% | 4.04% | 5.96% | 5.33% | 3.62% | 7.48% | 2.85% | 4.48% | 4.47% | 4.65% | 4.88% | 6.07% | 5.17% | 5.17% | 3.43% | 5.10% | 3.56% | 2.92% | 3.17% | 2.82% | 1.86% | 1.80% | 1.08% | -3.99% | 2.08% | 3.36% | 0.27% | 6.13% | 7.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 836.00M | 762.00M | 485.00M | 1.31B | 763.00M | 391.00M | 1.57B | 938.00M | 1.16B | 1.02B | 690.00M | 689.00M | 816.00M | 650.17M | 562.09M | 345.69M | 455.62M | 274.66M | 113.23M | 135.84M | 115.78M | 67.18M | 65.91M | 24.00M | -22.00M | 74.00M | 97.00M | 6.00M | 98.00M | 81.00M | 54.00M | 109.00M | 200.00M | 180.50M |
| Net Income | 2.49B | 2.81B | 2.93B | 3.37B | 2.71B | 1.68B | 2.45B | 614.00M | 1.28B | 1.15B | 1.23B | 1.22B | 1.42B | 1.10B | 1.04B | 647.15M | 833.68M | 487.42M | 308.48M | 280.01M | 228.93M | 142.76M | 117.17M | 90.00M | -382.00M | 129.00M | 173.00M | 12.00M | 190.00M | 176.00M | 89.00M | 122.70M | 355.00M | 309.60M |
| Net Income Ratio | 2.34% | 3.02% | 3.53% | 4.36% | 4.17% | 2.96% | 4.55% | 1.13% | 2.35% | 2.36% | 2.98% | 3.12% | 3.85% | 3.25% | 3.36% | 2.24% | 3.30% | 2.28% | 2.14% | 2.14% | 1.87% | 1.27% | 1.15% | 0.86% | -3.78% | 1.32% | 2.15% | 0.18% | 4.04% | 4.82% | 2.84% | 3.03% | 6.05% | 6.38% |
| EPS | 20.09 | 22.20 | 22.79 | 25.47 | 20.20 | 12.24 | 16.94 | 4.11 | 8.54 | 7.44 | 7.81 | 7.56 | 8.58 | 6.55 | 6.21 | 3.87 | 5.00 | 2.97 | 1.91 | 1.75 | 1.41 | 0.85 | 0.71 | 0.54 | -2.28 | 0.77 | 1.06 | 0.07 | 1.17 | 1.10 | 0.56 | 0.77 | 2.26 | 3.00 |
| EPS Diluted | 20.00 | 22.08 | 22.67 | 25.31 | 20.10 | 12.16 | 16.81 | 4.07 | 8.44 | 7.36 | 7.73 | 7.47 | 8.46 | 6.47 | 6.15 | 3.83 | 4.91 | 2.90 | 1.87 | 1.72 | 1.38 | 0.83 | 0.70 | 0.54 | -2.28 | 0.77 | 1.05 | 0.07 | 1.16 | 1.10 | 0.55 | 0.77 | 2.26 | 3.00 |
| Weighted Avg Shares Out | 123.87M | 126.42M | 128.69M | 132.20M | 134.05M | 137.49M | 144.49M | 149.37M | 149.45M | 154.19M | 157.50M | 161.48M | 165.41M | 167.78M | 167.36M | 167.17M | 166.87M | 164.12M | 161.51M | 160.01M | 158.68M | 167.95M | 165.03M | 166.76M | 167.73M | 167.48M | 163.41M | 162.53M | 162.27M | 160.00M | 158.93M | 159.35M | 157.08M | 101.13M |
| Weighted Avg Shares Out (Dil) | 124.44M | 127.09M | 129.40M | 133.01M | 134.73M | 138.40M | 145.58M | 150.92M | 151.14M | 155.87M | 159.15M | 163.46M | 167.83M | 169.80M | 169.07M | 168.97M | 169.82M | 168.08M | 164.96M | 162.80M | 162.13M | 171.99M | 167.39M | 166.76M | 167.73M | 167.48M | 165.84M | 165.28M | 164.59M | 160.79M | 161.82M | 159.35M | 157.08M | 101.13M |
Humana: Medicare Advantage Is Just A Short-Term Problem
Humana's stock has declined 18% while the S&P 500 returned 13.5%, driven by short-term issues with Medicare Advantage. Despite short-term cost challenges, Medicare Advantage remains a long-term tailwind, and CenterWell coordinated care isn't priced into Humana's strategy. I maintain buy...
AM Best Downgrades Credit Ratings of Humana Health of Puerto Rico Group's Subsidiaries; Affirms Credit Ratings of Humana Inc. and Most of Its Health Insurance Subsidiaries
OLDWICK, N.J.--(BUSINESS WIRE)-- #insurance--AM Best has downgraded the Financial Strength Rating (FSR) to B+ (Good) from B++ (Good) and the Long-Term Issuer Credit Rating (Long-Term ICR) to “bbb-” (Good) from “bbb” (Good) of Humana Insurance of Puerto Rico, Inc. and...
Humana says Susan Diamond to step down as CFO
Humana Inc said on Tuesday that Chief Financial Officer Susan Diamond was stepping down and Celeste Mellet would replace her, effective Jan. 11.
Humana Announces CFO Transition
LOUISVILLE, Ky.--(BUSINESS WIRE)--Leading health and well-being company Humana Inc. (NYSE: HUM) announced today that Celeste Mellet will be appointed to succeed Susan Diamond as Chief Financial Officer (CFO), effective January 11, 2025. Diamond is stepping down after a successful 18-year...
Humana (HUM) Up 15.1% Since Last Earnings Report: Can It Continue?
Humana (HUM) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports